Genedata Biologics リリース：
業界初のバイオロジクスデータ管理・解析プラットフォーム

First-in-class, off-the-shelf software platform automates and streamlines biologics discovery and development processes—from antibody screening to protein engineering and production

February 23, 2011
San Francisco, CA, USA

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of Genedata Biologics™, a first-in-class, off-the-shelf software solution for comprehensive data management and analysis of biologics R&D activities. Genedata Biologics streamlines and automates the complex biologics lead generation and optimization process, including antibody screening, protein engineering, and protein production. By supporting the complete R&D workflow, it enables pharmaceutical and biotechnology research organizations to efficiently discover and develop novel protein-based therapies. Genedata Biologics also enables registration of all relevant biomaterials to provide a historical record in support of downstream development and production of therapeutic proteins. Genedata Biologics is the result of long-term collaborations among Genedata and several of its pharmaceutical and biotech partners, including Bayer HealthCare Pharmaceuticals. The new Genedata Biologics platform will be featured at the Molecular Med Tri-Con 2011 (Moscone Convention Center, Feb. 23–25).

“Our collaboration with Genedata to develop a biologics data platform has been very successful,” said Dr. Clive Wood, Head of Global Biologics at Bayer HealthCare Pharmaceuticals. “A commercial data management solution such as this has been sorely lacking in protein therapeutics.”

“Protein-based medicines are the new frontier in the development of innovative therapies, and biologics is a major business focus for Genedata,” noted Dr. Othmar Pfannes, CEO of Genedata. “Our deep domain expertise in managing sequence data combined with our understanding of complex research processes is brought to bear in Genedata Biologics. We are committed to the advancement of Genedata Biologics and will continue to make significant investments that give researchers an innovative software platform for their biologics discovery—today and in the future.”

Industry’s First Commercial System for Biologics Compound & Sequence Registration
Genedata Biologics is the first, fully integrated data management and analysis platform for supporting the entire biologics R&D process. It uniquely integrates complex and interconnected workflows from different research groups and supports work in division-of-labor environments. By providing standardized interfaces, Genedata Biologics helps to document and manage a broad range of activities such as antibody screening (including phage display or hybridoma), cloning, molecular biology, protein expression and purification, analytics, and cell line development. In addition, the system provides functionalities to facilitate data and material handovers among different departments and external service providers. It provides significant built-in business- and lab-logic with integration capabilities to company-specific infrastructure and processes.

Aligned with the biologics R&D process, the Genedata Biologics Oracle^®-based database enables consistent storage and referencing of all relevant biomaterials such as antibody clones, vectors, and cell lines. It incorporates a variety of protein and nucleotide sequence information and assay and analytics readouts (e.g. Biacore, ELISA, FACS, etc.) generated along the process. Its modular architecture meets user-specific requirements, which allows the solution to be used through the R&D workflow. Current modules are available for Screening, Protein Engineering and Optimization, and Protein Production.

To schedule a product demonstration, email:  biologics(at)genedata.com.